Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
about
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.Natalizumab treatment of multiple sclerosis: new insights.Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
P2860
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Switching patients at high ris ...... her disease-modifying therapy.
@en
Switching patients at high ris ...... her disease-modifying therapy.
@nl
type
label
Switching patients at high ris ...... her disease-modifying therapy.
@en
Switching patients at high ris ...... her disease-modifying therapy.
@nl
prefLabel
Switching patients at high ris ...... her disease-modifying therapy.
@en
Switching patients at high ris ...... her disease-modifying therapy.
@nl
P2093
P2860
P1433
P1476
Switching patients at high ris ...... her disease-modifying therapy.
@en
P2093
Angharad Davis
Benjamin Turner
Klaus Schmierer
Sharmilee Gnanapavan
P2860
P304
P356
10.1136/PRACTNEUROL-2015-001355
P577
2016-04-25T00:00:00Z